An introduction to drug testing methods, terminology, specimen types, detection windows, and how workplace testing programs operate — everything employers and individuals need to understand before testing begins.
Drug testing is the technical analysis of a biological specimen to detect the presence of drugs or their metabolites — the chemical byproducts left in the body after a substance is processed and partially eliminated. The specimen analyzed may be urine, blood, saliva, hair, or sweat, depending on the purpose of the test, the substances being screened, and the detection window required.
In workplace settings, drug testing is used to maintain safety, deter substance use, establish compliance with legal requirements, and manage liability. In healthcare, legal, sports, and court-ordered settings, testing serves similar safety and compliance functions. The primary goal across all contexts is the same: to determine whether a person has used a substance within a detectable time window.
Employers use drug testing to reduce workplace accidents, protect employees and customers, and comply with federal or state regulations. DOT-regulated industries — trucking, aviation, railroad, transit — are legally required to maintain drug and alcohol testing programs for safety-sensitive employees. Non-DOT employers may establish their own programs based on company policy, insurance requirements, or industry standards.
Other common reasons for drug testing include pre-employment screening (confirming a job offer contingent on a negative test), random deterrence programs, post-accident investigations, reasonable suspicion testing when impairment is observed, and court-ordered or probation monitoring.
These terms are often used interchangeably but refer to different stages of the testing process. A drug screen (also called an immunoassay screen) is an initial, rapid analysis that indicates whether a specimen may contain drugs above a threshold level. It is fast, cost-effective, and suitable for high-volume testing — but it is less specific and can produce false positive results when medications or other substances cross-react with the test reagents.
A drug test in the confirmatory sense refers to the more precise follow-up analysis — typically gas chromatography/mass spectrometry (GC/MS) — used to confirm non-negative screen results. GC/MS identifies the exact substance present and its concentration, eliminating cross-reactivity errors. For certified workplace testing programs, confirmatory testing is required before any positive result can be reported to an employer.
A non-negative screen result does not mean a positive violation. It means the specimen requires confirmatory testing. The MRO (Medical Review Officer) reviews confirmed non-negative results, contacts the donor about any legitimate medical explanation, and issues the final verified result. Only after MRO review is a result reported to the employer as a confirmed positive or verified negative.
Each specimen type has different advantages, limitations, detection windows, and appropriate use cases. The choice of specimen directly affects what the test can and cannot detect.
The most widely used specimen type for workplace drug testing — non-invasive, cost-effective, and capable of detecting a broad range of substances. Required by DOT for all federal drug testing programs. Detects drug metabolites rather than the drug itself, which is why detection windows extend beyond the period of impairment.
Non-invasive and difficult to adulterate, saliva testing detects parent drugs (the drug itself) rather than metabolites — which means it reflects more recent use and correlates better with actual current impairment. Increasingly used for post-accident and reasonable suspicion testing where recency matters most.
Hair testing provides the longest detection window of any specimen type — approximately 90 days of drug use history from a standard 1.5-inch hair sample. It cannot detect very recent use (within the past 5–7 days while the hair grows). Used when identifying long-term or historical drug use patterns is more important than recent use detection.
Blood testing provides the most accurate picture of drug concentration at the time of testing — making it valuable in legal proceedings and post-accident investigations where proving current impairment matters. More invasive and expensive than urine testing, and requires trained phlebotomy personnel for collection.
Sweat testing uses a patch worn on the skin that continuously collects sweat over an extended monitoring period — typically 7–14 days. The patch is then analyzed for drug presence. Less common in standard workplace testing but used in probation monitoring, court-ordered supervision, and treatment programs requiring continuous surveillance.
Most employer programs use urine — it's accepted for DOT compliance and provides broad substance coverage at low cost. Oral fluid is growing for roadside and post-accident use. Hair is used when historical use matters more than recency. Call (816) 442-0295 to discuss which method fits your testing program.
Detection windows vary significantly by substance, specimen type, frequency of use, individual metabolism, and body composition. The ranges below represent typical detection for occasional to regular users — heavy chronic use can significantly extend these windows.
| Substance | Urine | Saliva | Blood | Hair |
|---|---|---|---|---|
| Marijuana (THC) | 1–30 days (up to 90 heavy) | 24–72 hours | 2–7 days | Up to 90 days |
| Cocaine | 2–4 days | 1–2 days | 12–24 hours | Up to 90 days |
| Opiates (Codeine, Morphine) | 1–3 days | 1–4 days | 12 hours | Up to 90 days |
| Amphetamines / Meth | 1–4 days | 1–3 days | 24–48 hours | Up to 90 days |
| Phencyclidine (PCP) | 7–14 days | 1–3 days | 24 hours | Up to 90 days |
| Benzodiazepines | 3 days – 6 weeks | 1–5 days | 24–48 hours | Up to 90 days |
| Barbiturates | 2 days – 3 weeks | 1–2 days | 1–3 days | Up to 90 days |
| Methadone | 3–12 days | 1–3 days | 24–36 hours | Up to 90 days |
| Alcohol | 7–12 hours (urine ethanol) | 12–24 hours | 3–10 hours | Not typical |
The ranges in this table are general estimates for occasional to moderate users. Chronic daily use, higher body fat percentage (which stores THC longer), slower metabolism, and high doses can all significantly extend detection beyond these ranges. Conversely, infrequent use of short-acting substances may clear faster than the low end of the range. Detection windows should not be used to predict when a test will return negative — individuals metabolize substances differently.
Drug test results fall into four categories. Understanding what each means — and what happens next — is essential for both employers and individuals.
No drugs were detected above the established cutoff level. For certified workplace testing, a negative result is reviewed by the MRO and then reported directly. The employee or applicant may proceed without restriction.
Drugs were detected above the cutoff level, confirmed by GC/MS, and verified by the MRO after the donor had the opportunity to explain any legitimate medical reason. A verified positive is a confirmed DOT or employer policy violation.
The initial screen returned non-negative — meaning a substance was detected above screening thresholds — but the result has not yet been confirmed. Requires GC/MS confirmatory testing and MRO review before a final result is issued. "Non-negative" is not the same as "positive."
Drug test accuracy is high — but not perfect. Initial immunoassay screens can produce false positive results due to cross-reactivity with other substances, including over-the-counter medications, prescription drugs, and certain foods. This is precisely why certified testing programs require confirmatory GC/MS testing before any positive result is reported.
A false positive occurs when an initial screen indicates the presence of a drug that is not actually present — or returns a non-negative result due to a legal substance cross-reacting with the test reagent. Common causes of false positives on immunoassay screens include:
GC/MS confirmatory testing eliminates virtually all false positives — it identifies the specific substance and its concentration with a precision that immunoassay screens cannot achieve. This is why GC/MS is mandatory before any positive result is reported in certified testing programs.
The Medical Review Officer (MRO) is a licensed physician trained in drug testing who receives all non-negative laboratory results before they are reported to the employer. The MRO's role is to ensure the accuracy and fairness of the result. Before issuing a verified positive result, the MRO contacts the donor directly to determine whether there is a legitimate medical explanation — such as a valid prescription for a detected substance. If the donor provides adequate medical documentation, the MRO may verify the result as negative even if the lab confirmed the substance's presence.
For DOT testing, the MRO process is a federal requirement. For non-DOT programs, MRO review is best practice and protects both the employer and the employee from false positive violations.
If you take any prescription medications — especially opioids, benzodiazepines, stimulants, or sedatives — disclose them at the collection site during intake. This creates a record prior to the test. The MRO will contact you if a non-negative result requires explanation, and prior disclosure helps the process go smoothly. Disclosing a prescription does not guarantee a negative result — but it ensures the MRO has context for their review.
These terms appear throughout drug testing documentation, results reports, and employer policies. Understanding them prevents confusion about what results mean and what actions are required.
A rapid antibody-based screening technique used to detect drug presence above a cutoff threshold. Fast and cost-effective, but not substance-specific — cross-reactivity with medications can produce false positives. Any non-negative immunoassay result must be confirmed by GC/MS before being reported as positive.
The gold-standard confirmatory testing method. GC/MS separates and identifies chemical compounds with extreme precision — it can distinguish between structurally similar substances and measure their exact concentration. Virtually eliminates false positives from immunoassay cross-reactivity. Required for confirmatory testing in all certified programs.
The minimum concentration at which a substance must be present for the test to report a non-negative result. Below the cutoff, the result is reported as negative even if trace amounts are present. Cutoff levels are set by regulatory bodies (SAMHSA for federal programs) or by employers for non-DOT programs.
The documented process that tracks a specimen from collection through laboratory analysis and result reporting. Each transfer of the specimen is documented with signatures, timestamps, and tamper-evident sealing. An unbroken chain of custody is required for results to be legally defensible and admissible in legal or regulatory proceedings.
The chemical compound produced when the body processes (metabolizes) a drug. Most urine drug tests detect metabolites rather than the drug itself — which is why detection windows extend beyond the period of actual drug effects or impairment. THC metabolites, for example, can be detected weeks after the high has worn off.
A licensed physician with specialized training in drug testing who reviews all non-negative laboratory results before they are reported to employers. The MRO contacts the donor to verify any legitimate medical explanation — including valid prescriptions — and issues the final verified result. Required for all DOT testing programs.
The Substance Abuse and Mental Health Services Administration — a federal agency whose laboratory certification standards (HHS-certified labs) are required for all DOT drug testing. Only SAMHSA-certified laboratories are authorized to analyze specimens for federal workplace drug testing programs. Non-SAMHSA labs are not acceptable for DOT compliance.
DOT drug tests follow strict federal regulations under 49 CFR Part 40 — including SAMHSA-certified labs, specific collection procedures, federal CCF forms, and mandatory MRO review. Non-DOT tests follow employer-defined procedures with fewer regulatory requirements. The two test types are not interchangeable — if your role requires DOT testing, a non-DOT test will not satisfy that requirement.
A well-designed employer drug testing program includes clear policies, multiple test circumstances, consistent application, and proper documentation. Here are the key components.
The most common starting point — a drug test conducted before extending a final employment offer. The conditional offer is contingent on a negative result. Pre-employment testing sets clear expectations and establishes a baseline for the program.
Employees are selected unpredictably throughout the year using a scientifically random process. The unpredictability is the deterrent — employees cannot plan around the test. DOT programs have minimum annual random testing rate requirements by agency.
Conducted after a workplace accident or incident to determine whether substance use was a contributing factor. DOT programs have specific triggering criteria and time windows. Non-DOT employers define their own incident-triggered testing thresholds in their policy.
When a trained supervisor observes specific, articulable signs of impairment — behavioral changes, coordination issues, odor — the employee is tested. Documentation of the observed signs must occur before or immediately after the test. This test type requires supervisor training for proper implementation.
After a violation, the employee must pass a return-to-duty test before resuming safety-sensitive work. Follow-up testing then continues for a defined period — at least 6 tests in 12 months for DOT programs — to ensure ongoing sobriety.
A legally sound drug testing program requires a clear written policy communicated to all employees before testing begins. The policy must define: which test types are used, when, what substances are tested, and what the consequences of a positive result are. Inconsistent application of the policy creates legal exposure.
More questions? Call (816) 442-0295 and we'll answer in two minutes.
Pre-employment, random, post-accident, court-ordered, DOT & non-DOT — certified chain-of-custody collection, MRO-reviewed results, all panel sizes available.
8101 E. Bannister Rd · Kansas City, MO 64134 · Cost: $60–$99 based on services needed
